Overview

AZA+Lus VS AZA Monotherapy in HR-MDS

Status:
NOT_YET_RECRUITING

Trial end date:
2027-01-31

Target enrollment:

Participant gender:

Summary

This study is a randomized, prospective, single-center, open-label cohort study involving untreated HR-MDS patients. The patients were divided randomized into AZA+Lus cohort and AZA monotherapy cohort.

Phase:

PHASE3

Details

Lead Sponsor:

Peking Union Medical College Hospital

Treatments:

Azacitidine
luspatercept